WASHINGTON — When President Trump delivered his much-ballyhooed address on drug prices in May, even supporters conceded there were more question marks among his policy ideas than concrete proposals.

But over the past week, the Trump administration has begun to put some periods at the ends of the sentences.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Why not go the whole hog and get rid of PBMs.
    They just make work/money from financial negotiations
    about who pays what money to whom. Parasites!
    Who needs them anyway? Just negotiate direct with the company.
    No brainer.

    Biosimilars?
    Biopharma has been hugely successful in blocking FDA from
    introducing sensible approval procedures for Biosimilars.
    EMA has been regulating them competently for many years.
    Over there the political will to work for the public good
    is alive and well of course.
    Nevertheless, DT says time is up, dudes.

    Small steps which may lead to giant leaps in mind set.

    • It is not easy to eliminate PBMs. They have a stranglehold on legislators in our legally corrupt political system. Only way at least I see is ease them out. Slow death could be a way.

      On Biopharm and Biosimilars pharma have a stranglehold like PBMs. Greed and greed is their way to fleece patients. Ironically not very many patients outside the developed countries can afford their offerings. They don’t have mutually subsidized system.

  • Direct importation of generics that can bypass the PBMs and selling via PillPack ( Amazon subsidiary) could make a HUGE dent in drug pricing. PBMs will resist and challenge importation as being unsafe. However, based on import records the drugs could be imported at about one fourth the price and sold in the US.

    I presented my perspective earlier this year in the linked blog.

    Improving Drug Affordability for the United States Populous through Alternate Business Models :https://pharmachemicalscoatings.blogspot.com/2018/05/improving-drug-affordability-for-united.html
    Things can happen if an effort is made.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy